Rain didn’t stop the Houston-area pulmonary hypertension (PH) community from raising more than $19,000 at its first O2breathe walk. The Jan. 28 at Buffalo Bayou Partnership Water Works-Brown Foundation celebrated participants, patients and top fundraisers.
Amazon is ending its AmazonSmile donation program, which many Pulmonary Hypertension Association (PHA) supporters took part in. If you'd like to continue supporting PHA programs through everyday purchases, consider using our new "round-up" feature for online giving.
Paul Critser, M.D., Ph.D., has received the Pulmonary Hypertension Association Pediatric PH Research Award.
The Pulmonary Hypertension Association (PHA) is pleased to announce Paul Crister, M.D., Ph.D., as the recipient of the 2022 Pediatric PH Research Award. The research award supports research that could have a great impact toward advancing the field of PH pediatrics.
Chloe Merritt, 22, is still getting used to a low-sodium diet, lack of energy and the challenges of a subcutaneous pump after her September 2022 diagnosis. But the life-changing experience has brought her closer than ever to family and friends. And it led her to a new favorite food. Chloe shares her positive outlook in the Right Heart Blog.
The Pulmonary Hypertension Association recently merged its telephone support groups with its nationwide support group program. All nationwide support group meetings are now conducted through Zoom. The online meetings allow people with shared experiences or interests to connect wherever they live.
The latest issue of Advances in Pulmonary Hypertension addresses associated diseases that can lead to pulmonary hypertension (PH). Advances is the Pulmonary Hypertension Association’s quarterly peer-reviewed clinical journal.
Pulmonary Hypertension Association support groups came together for holiday cheer, many for the first time since the pandemic. Get a glimpse of the celebrations in this round-up. Read more and browse the photos.
Population: Pulmonary Arterial Hypertension in adults ages 18-75 years old (inclusive) Start Date: May 19, 2021 End Date: February 9, 2026 Phase: Phase 2/Phase 3 Institution: Multi-center Study Website: https://www.INSIGNIA-PAHstudy.com The INSIGNIA-PAH Clinical Trial will test an investigational drug in adults ages 18 to 75 who have pulmonary
